|
**Overview**: Myotonic Dystrophy Type 2 Panel**Introduction**: The Myotonic Dystrophy Type 2 Panel is a diagnostic tool designed to screen for myotonic dystrophy type 2 using whole blood samples. In India, DM2 (proximal myotonic myopathy, CNBP CCTG repeats) is rarer than DM1 but presents with proximal weakness, myotonia, and milder cardiac involvement, often underdiagnosed due to variable phenotype. High morbidity from delayed recognition in rural/low-SES adults with muscle pain/weakness or cataracts, limited genetic labs, delayed supportive care leading to falls or cardiac issues. Per neurology practices aligned with ICMR and Indian Academy of Neurology guidelines, the test employs PCR for ZNF9 CNBP repeats and mutation status over 1-2 days with high accuracy, valuable for confirming DM2 in suspected proximal myopathy. This diagnostic falls under genetic disorder screening and targets patients with adult-onset proximal weakness or family history, addressing accurate detection to guide cardiac monitoring and physical therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise molecular confirmation and reducing neuromuscular disability. Its whole blood-based approach ensures reliable repeat expansion detection.**Other Names**: Myotonic 2 Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/cytogenetics, compliant with 2025 standards.**Historical Milestone**: CNBP repeat testing standard; in India, reported in neuromuscular cases.**Purpose**: The test assesses 2 parameters including ZNF9 CNBP repeats to guide DM2 screening, confirm expansion, inform counseling.**Test Parameters**: 1. ZNF9 CNBP Repeats, 2. Mutation Status.**Pretest Condition**: No fasting required; patients should have proximal weakness or myotonia.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve DNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for PCR).**Medical History**: Patients should provide details on muscle pain, cataracts, family history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed DM2 including weakness progression, benefits of confirmation, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and size repeats within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Expanded CNBP repeats confirm DM2, necessitating specialist input.**Specialist Consultation**: Neurologists or geneticists should be consulted for management.**Additional Supporting Tests**: EMG, cardiac evaluation for confirmation.**Test Limitations**: Repeat size interpretation complex; comprehensive approach required.**References**: Indian Journal of Neurology 2024, Neuromuscular Studies India 2023. |
